A Study of LY3841136 in Overweight and Obese Participants

NCT06345066 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug LY3841136 in adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 96 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-04 · est. completion 2025-09

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06345066 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Treatments tested

Tirzepatide Drug

Administered SC.
LY3841136 Drug

Administered SC.
Placebo Drug

Administered SC.

Main thing measured	Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06345066 ↗